Dyne Therapeutics, Inc. (DYN)
21.13
+0.19
(+0.91%)
USD |
NASDAQ |
Jun 29, 15:44
Dyne Therapeutics Cash from Investing (TTM) : -32.60M for March 31, 2026
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | -32.60M |
| December 31, 2025 | -28.75M |
| September 30, 2025 | -45.74M |
| June 30, 2025 | -27.18M |
| March 31, 2025 | -22.78M |
| December 31, 2024 | -204.08M |
| September 30, 2024 | -161.87M |
| June 30, 2024 | -129.65M |
| March 31, 2024 | -123.59M |
| December 31, 2023 | 83.31M |
| Date | Value |
|---|---|
| September 30, 2023 | 76.35M |
| June 30, 2023 | 115.19M |
| March 31, 2023 | 116.40M |
| December 31, 2022 | 87.20M |
| September 30, 2022 | 67.73M |
| June 30, 2022 | 13.22M |
| March 31, 2022 | -11.65M |
| December 31, 2021 | -137.89M |
| September 30, 2021 | -182.88M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| Vor Biopharma, Inc. | -311.81M |
| Agenus, Inc. | 70.09M |
| Amgen, Inc. | -2.212B |
| Anika Therapeutics, Inc. | -3.312M |
| BioCryst Pharmaceuticals, Inc. | -309.44M |